ESH AL 2018 | Novel agents in trials for AML: quizartinib and gilteritinib

Mark Levis

At the 2018 European School of Haematology (ESH) Clinical Updates on Acute Leukaemias, held in Budapest, Hungary, Mark Levis, MD, PhD, from Sidney Kimmel Comprehensive Cancer Centre, Baltimore, MD, gives us an update on novel chemotherapeutic agents for acute myeloid leukemia (AML). The majority of these novel agents target either FLT3 or IDH, such as midostaurin, quizartinib and gilteritinib, which are being tested at every disease stage. Although promising results have been produced, there has been resistance through signaling pathways such as Ras; thus, these agents may require testing in combination regimens.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter